Yong Tao

Prof. Yong Tao


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in Biology
Verified
Journal Article
Open access
PDF file
QYQiyan Yin
Qiyan Yin
FQFen Qin
Fen Qin
FGFangliu Gan
Fangliu Gan
GZGuangxi Zhao
Guangxi Zhao
RCRonghua Chen
Ronghua Chen
YTYong Tao
Yong Tao
Colorectal cancer (CRC) incidence increases markedly with age, yet chronological age is an inadequate proxy for the complex biological processes involved. Colon aging, the intrinsic biological aging of the colonic tissue, is emerging as a crucial, active driver of CRC development. This review comprehensively analyzes the interplay between colon aging and CRC pathogenesis by examining fundamental hallmarks of aging—such as altered tissue homeostasis, epigenetic dysregulation, and microenvironmental shifts including chronic inflammation (inflammaging), gut microbiome dysbiosis, and extracellular matrix remodeling—manifest specifically within the aging colon to synergistically foster a pro-tumorigenic environment. Key findings synthesized from the literature highlight the critical roles of impaired colonic stem cell function, epithelial barrier disruption (“leaky gut”), persistent low-grade inflammation, and altered microbial communities and their metabolites in promoting CRC initiation and progression. Translating this mechanistic understanding holds significant promise: insights from colon aging research can inform novel biomarkers for improved early detection and risk stratification, guide the development of personalized preventative strategies and therapeutic interventions targeting aging pathways, and underpin public health initiatives focused on healthy colon aging. Ultimately, recognizing colon aging as a modifiable contributor to CRC offers a powerful avenue to potentially reduce CRC incidence and enhance patient outcomes, particularly in the vulnerable aging population.

25 August 2015 in bioRxiv
Verified
Preprint
Open access
PDF file
YTYong Tao
Yong Tao
ZHZheng Hu
Zheng Hu
SLShaoping Ling
Shaoping Ling
SYShiou-Hwie Yeh
Shiou-Hwie Yeh
WZWeiwei Zhai
Weiwei Zhai
CWChung-I Wu
Chung-I Wu
S: The genetic diversity within a single tumor can be extremely large, possibly with mutations at all coding sites (Ling et al. 2015). In this study, we analyzed 12 cases of multiple hepatocellular carcinoma (HCC) tumors by sequencing and genotyping several samples from each case. In 10 cases, tumors are clonally related by a process of cell migration and colonization. They permit a detailed analysis of the evolutionary forces (mutation, migration, drift and natural selection) that influence the genetic diversity both within and between tumors. In 23 inter-tumor comparisons, the descendant tumor usually shows a higher growth rate than the parent tumor. In contrast, neutral diversity dominates within-tumor observations such that adaptively growing clones are rarely found. The apparent adaptive evolution between tumors can be explained by the inherent bias for detecting larger tumors that have a growth advantage. Beyond these tumors are a far larger number of clones which, growing at a neutral rate and too small to see, can nevertheless be verified by molecular means. Given that the estimated genetic diversity is often very large, therapeutic strategies need to take into account the pre-existence of many drug-resistance mutations. Importantly, these mutations are expected to be in the very low frequency range in the primary tumors (and become frequent in the relapses, as is indeed reported (1-3). In conclusion, tumors may often harbor a very large number of mutations in the very low frequency range. This duality provides both a challenge and an opportunity for designing strategies against drug resistance (4-8). One Sentence Summary: The total genetic diversity across all tumors of a single patient, with large number of low frequency mutations driven by neutral and adaptive forces, presents both a challenge and an opportunity for new cancer therapeutics.

9 July 2026 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SCShiqi Chang
Shiqi Chang
DLDi Lu
Di Lu
YJYuyuan Jin
Yuyuan Jin
YHYilei He
Yilei He
赵玥赵 玥
赵 玥
YTYong Tao
Yong Tao
Epigenetic editing achieves durable gene silencing through targeted modification of chromatin and DNA methylation states without altering the genomic sequence—modifications that remain fundamentally reversible compared with genome editing. Long constrained by transient efficacy, insufficient precision, and delivery bottlenecks, the field reached a critical inflection point in 2024–2025, measurable through three quantifiable criteria: (1) mechanistic durability—silencing maintained across ≥ 450 cell divisions in vitro and ≥ 12 months in vivo without continued editor expression; (2) delivery competence—tissue-selective transduction at > 50% efficiency in liver, muscle, and whole brain via engineered lipid nanoparticle and AAV platforms; and (3) clinical validation—advancement of multiple first-in-human trials. The inaugural trial in epigenetic editing was OTX-2002 (targeting MYC-driven malignancies, MYCHELANGELO study), initiated in October 2022, followed by TUNE-401 for chronic hepatitis B (Phase Ib, November 2024) and EPI-321 for facioscapulohumeral muscular dystrophy (Phase I/II, first patient dosed August 2025). Artificial intelligence contributes at distinct levels: deep learning platforms have directly accelerated clinical-stage LNP formulation screening and AAV capsid prediction; AlphaFold3 has optimized protein–DNA interaction validation without yet entering clinical programs; and the 2025 de novo design of DNA-binding proteins smaller than 65 amino acids represents a proof-of-concept breakthrough with zero clinical precedent. This review comprehensively analyzes epigenetic editing’s technological maturation, provides a tiered assessment of AI’s realized and anticipated contributions, critically evaluates the emerging clinical landscape, and identifies decisive unresolved challenges—including long-term stability in non-dividing cells, the lack of monitoring systems and intervention protocols needed to implement reversibility in clinical practice, and manufacturing access barriers. We argue that epigenetic editing is progressively establishing itself as a distinctive therapeutic modality characterized by durable efficacy and sequence-independent safety—reversibility as a theoretical safety mechanism has been validated preclinically, but the monitoring and intervention infrastructure required for its clinical implementation remains to be established. Long-term human validation remains the outstanding core question.

5 October 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
悦张悦正 张
悦正 张
YLYawei Li
Yawei Li
XSXu Shen
Xu Shen
TZTianqi Zhu
Tianqi Zhu
YTYong Tao
Yong Tao
XLXuemei Lu
Xuemei Lu
ABSRACT: Large and non-recombining genomes are prone to accumulating deleterious mutations faster than natural selection can purge (Muller’s ratchet). A possible consequence would then be the extinction of small populations. Relative to most single-cell organisms, cancer cells, with large and non-recombining genomes, could be particularly susceptible to such “mutational meltdown”. Curiously, deleterious mutations in cancer cells are rarely noticed despite the strong signals in cancer genome sequences. Here, by monitoring single-cell clones from HeLa cell lines, we characterize deleterious mutations that retard cell proliferation. The main mutational events are copy number variations (CNVs), which happen at an extraordinarily high rate of 0.29 events per cell division. The average fitness reduction, estimated to be 18% per mutation, is also very high. HeLa cell populations therefore have very substantial genetic load and, at this level, natural population would likely experience mutational meltdown. We suspect that HeLa cell populations may avoid extinction only after the population size becomes large. Because CNVs are common in most cell lines and cancer tissues, the observations hint at cancer cells’ vulnerability, which could be exploited by therapeutic strategies.